EQ · XBRL financial data

Equillium financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EQ's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 12, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	9,124	8,870	9,211*	10,689	13,853	12,161	4,392*	—	—	—	—	—
Research and development	—	—	year only	—	—	—	—	—	—	—	—	—
General and administrative	3,105	3,519	3,227*	3,737	3,145	3,278	1,775*	2,946	—	3,274	2,619	2,406
Total operating expenses	12,715	12,493	12,411*	13,480	13,953	12,840	9,090*	8,870	—	4,575	5,610	5,155
Operating income (loss)	(3,591)	(3,623)	(3,200)*	(2,791)	(100)	(679)	(4,698)*	(8,870)	—	(4,575)	(5,610)	(5,155)
Interest income	627	551	517*	439	371	331	239*	173	—	235	309	509
Interest expense	259	0*	0*	—	—	—	—	—	—	—	—	—
Other income (expense)	(112)	(142)	357*	(382)	—	—	—	—	—	—	—	—
Income tax expense (benefit)	8	496	16*	0	0	0	361*	0	—	0	—	—
Net income (loss)	(3,343)	(3,710)	(2,342)*	(2,734)	468	(7)	(5,794)*	(8,654)	—	(4,230)	(5,311)	(4,693)
Earnings per share, basic USD per share	(0.10)	(0.11)	(0.07)*	(0.08)	0.01	0.00	(0.16)*	(0.24)	—	(0.06)	(0.06)	(0.04)
Earnings per share, diluted USD per share	(0.10)	(0.11)	(0.07)*	(0.08)	0.01	0.00	(0.17)*	(0.24)	—	(0.06)	(0.06)	(0.04)
Weighted average shares, basic thousands of shares	34,450	34,879	35,153*	35,255	35,292	35,424	35,458*	35,587	—	65,323	96,279	111,806
Weighted average shares, diluted thousands of shares	34,450	34,879	35,153*	35,255	36,590	35,424	34,174*	35,587	—	65,323	96,279	111,806

Balance sheet

CSV

Fiscal quarters (EQ's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 12, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	25,624	34,382	23,216	11,568	11,057	15,448	18,085	14,502	—	33,120	61,322	57,164
Marketable securities	22,754	11,924	17,650	20,717	22,242	10,429	4,490	0	—	0	—	—
Accounts receivable	3,743	3,769	3,735	5,048	5,893	5,009	0	—	—	—	—	—
Prepaid and other current assets	5,235	3,836	4,748	5,147	2,695	2,760	2,403	1,714	—	459	953	812
Total current assets	57,356	53,911	49,349	42,480	41,887	33,646	24,978	16,216	—	33,579	62,275	57,976
Property and equipment, net	329	313	315	361	329	293	262	233	—	174	214	188
Right-of-use asset	992	922	796	694	592	473	364	280	—	753	567	475
Total assets	58,764	55,225	50,530	43,597	42,861	34,457	25,604	16,729	—	34,506	63,083	58,666
Accounts payable	3,026	3,635	4,707	2,778	4,486	3,666	2,676	3,058	—	1,082	1,295	850
Accrued liabilities	7,537	8,304	6,697	5,646	6,903	5,049	3,483	2,798	—	1,740	1,609	1,216
Total current liabilities	25,218	28,199	27,573	22,208	20,169	11,057	6,356	6,002	—	3,094	3,345	2,478
Lease liability, non-current	609	498	384	295	259	223	187	149	—	473	251	172
Total liabilities	31,783	31,117	27,957	22,503	20,428	11,280	6,543	6,151	—	3,567	3,596	2,650
Accumulated deficit	(179,688)	(183,398)	(185,740)	(188,474)	(188,006)	(188,013)	(193,807)	(202,461)	—	(212,430)	(221,516)	(226,209)
Total stockholders' equity	26,981	24,108	22,573	21,094	22,433	23,177	19,061	10,578	—	30,939	59,487	56,016
Total liabilities and equity	58,764	55,225	50,530	43,597	42,861	34,457	25,604	16,729	—	34,506	63,083	58,666
Common shares outstanding (cover page) thousands of shares	34,569	35,119	35,255	35,255	35,424	35,431	35,610	35,719	59,503	60,893	63,227	63,408

Cash flows

CSV

Fiscal quarters (EQ's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Aug 12, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,343)	(3,710)	(2,342)*	(2,734)	468	(7)	(5,794)*	(8,654)	—	(4,230)	(5,311)	(4,693)
Stock-based compensation	934*	979*	1,046*	972	952*	1,005*	821*	621	—	401*	930	1,088*
Net cash from operating activities	(6,215)*	(1,909)*	(5,664)*	(8,800)	730*	(7,657)*	(3,299)*	(8,169)	—	(8,431)*	(4,301)	(4,107)*
Purchases of property and equipment	—	—	35*	19	62*	0*	4*	4	—	0*	3	71*
Net cash from investing activities	15,000*	10,985*	(5,566)*	(2,831)	(1,351)*	12,000*	5,996*	4,496	—	0*	(3)	(71)*
Proceeds from issuing equity	—	—	—	—	—	—	—	—	—	30,000	35,000	—
Share repurchases	—	—	0*	—	—	—	—	—	—	—	—	—
Net cash from financing activities	(7,618)*	(260)*	79*	—	—	0*	73*	91	—	30,069*	35,346	42*
Net change in cash	1,121*	8,758*	(11,166)*	(11,648)	(511)*	4,391*	2,637*	(3,583)	—	21,625*	31,045	(4,158)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Equillium	57,164	not reported	(4,107)*	63.4M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026
Minerva Neurosciences	24,652	not reported	(13,345)*	47.7M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.